USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
POTENTIA PHARMACEUTICALS, INC
Address:
POTENTIA PHARMACEUTICALS, INC
201 E JEFFERSON ST, STE 312
LOUISVILLE, KY 40202
Phone:
N/A
URL:
N/A
EIN:
43575012
DUNS:
144375263
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $756,798.00 2
STTR Phase I $635,758.00 2
STTR Phase II $977,329.00 1

Award List:

Bypassing fluidics in proteomic screening

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$504,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new, groundbreaking technology for the rapid identification of ligands for proteins. Every year, the pharmaceuticals industry loses about $3 billion by targeting genes/proteins wrongfully identified as the cause of… More

Modified bacterial system for vivo direction evolution

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$252,798.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new genetic system that will mimic the natural process of evolution for a selected subset of genes inside of a bacterial cell. Instead of an evolutionary time scale of years, evolution will proceed at an accelerated rate… More

Targeting drug delivery nanoparticles to sites of inflammation

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$977,329.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a nanoparticle-based drug delivery system for use in the treatment of dry age-related macular degeneration (AMD). AMD is the leading cause of blindness for individ uals over fifty-five years of age that live… More